Durvalumab with chemo approved for endometrial cancer

FDA approved durvalumab (Imfinzi) with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent endometrial cancer that's mismatch repair deficient (dMMR). Approval was based on data from the DUO-E trial. While a statistically significant improvement in progression-free survival was seen in the overall population for durvalumab with carboplatin plus paclitaxel vs. carboplatin and paclitaxel alone, the improvement in the overall population was primarily attributed to patients with dMMR tumors.